Marie Jaspard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marie Jaspard has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Eric Caumes
2 shared publicationsBahram Bodaghi
1 shared publicationDhiba Marigot-Outtandy
1 shared publicationElisabeth Elefant-Amoura
1 shared publication- Eric Caumes
Centre de Diagnostic et de Thérapeutique, Hotel Dieu Hôpital, 75004 Paris, France
1 shared publication - Françoise Le Pimpec-Barthes
Department of Thoracic Surgery and Lung Transplantation, Hôpital Européen Georges-Pompidou, Assistance Publique—Hôpitaux de Paris, Université Paris Cité , Paris, France
1 shared publication
Latest Publications
- 1 August 2020
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 26 (8) , 1792-1800
Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France
Linezolid is one of the most effective drugs for treating multidrug-resistant tuberculosis (MDR TB), but adverse effects remain problematic. We evaluated 57 MDR TB patients who had received >1 dose of linezolid during 2011–2016. Overall, patients received 600 mg/day of linezolid for a median of 13 months. In 33 (58%) patients, neurologic or ophthalmologic signs developed, and 18 (32%) had confirmed peripheral neuropathy, which for 78% was irreversible at 12 months after the end of TB treatment despite linezolid withdrawal. Among the 19 patients who underwent ophthalmologic evaluation, 14 patients had optic neuropathy that fully reversed for 2. A total of 16 (33%) of 49 patients had a linezolid trough concentration >2 mg/L, and among these, 14 (88%) experienced adverse effects. No significant association was found between trough concentration and neurologic toxicity. These findings suggest the need to closely monitor patients for neurologic signs and discuss optimal duration of linezolid treatment.
- 1 August 2020
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 26 (8) , 1792-1800
Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France
Linezolid is one of the most effective drugs for treating multidrug-resistant tuberculosis (MDR TB), but adverse effects remain problematic. We evaluated 57 MDR TB patients who had received >1 dose of linezolid during 2011–2016. Overall, patients received 600 mg/day of linezolid for a median of 13 months. In 33 (58%) patients, neurologic or ophthalmologic signs developed, and 18 (32%) had confirmed peripheral neuropathy, which for 78% was irreversible at 12 months after the end of TB treatment despite linezolid withdrawal. Among the 19 patients who underwent ophthalmologic evaluation, 14 patients had optic neuropathy that fully reversed for 2. A total of 16 (33%) of 49 patients had a linezolid trough concentration >2 mg/L, and among these, 14 (88%) experienced adverse effects. No significant association was found between trough concentration and neurologic toxicity. These findings suggest the need to closely monitor patients for neurologic signs and discuss optimal duration of linezolid treatment.
- 1 July 2020
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 36, 101732
Rasmussen aneurysm in a patient from the Ukraine: A diagnostic challenge
- 1 July 2020
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 36, 101732
Rasmussen aneurysm in a patient from the Ukraine: A diagnostic challenge
- Open Access
- 1 October 2017
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 23 (10) , 1731-1732
Bedaquiline and Linezolid for Extensively Drug-Resistant Tuberculosis in Pregnant Woman
A woman with extremely drug-resistant tuberculosis treated with a drug regimen including linezolid and bedaquiline during her last 3 weeks of pregnancy gave birth to a child without abnormalities. No fetal toxicities were noted by 2 years after delivery. This drug combination might be safe during the late third trimester of pregnancy.
- 1 October 2017
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 23 (10) , 1731-1732
Open AccessBedaquiline and Linezolid for Extensively Drug-Resistant Tuberculosis in Pregnant Woman
A woman with extremely drug-resistant tuberculosis treated with a drug regimen including linezolid and bedaquiline during her last 3 weeks of pregnancy gave birth to a child without abnormalities. No fetal toxicities were noted by 2 years after delivery. This drug combination might be safe during the late third trimester of pregnancy.